NASDAQ:AXSM - Axsome Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axsome Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $87.60 +0.63 (+0.72 %) (As of 01/28/2020 04:00 PM ET) Add Compare Today's Range$86.18Now: $87.60▼$88.3250-Day Range$46.79MA: $87.84▼$106.2452-Week Range$7.63Now: $87.60▼$109.94Volume384,345 shsAverage Volume911,006 shsMarket Capitalization$3.02 billionP/E RatioN/ADividend YieldN/ABeta3.39 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM Previous Symbol CUSIPN/A CIK1579428 Webhttp://axsome.com/ Phone212-332-3241Debt Debt-to-Equity Ratio2.80 Current Ratio2.39 Quick Ratio2.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book2,920.00Profitability EPS (Most Recent Fiscal Year)($1.15) Net Income$-30,970,000.00 Net MarginsN/A Return on Equity-430.09% Return on Assets-134.10%Miscellaneous Employees29 Outstanding Shares34,509,000Market Cap$3.02 billion Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive AXSM News and Ratings via Email Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AXSM Rates by TradingView Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics Inc (NASDAQ:AXSM) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.15. View Axsome Therapeutics' Earnings History. When is Axsome Therapeutics' next earnings date? Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Axsome Therapeutics. What price target have analysts set for AXSM? 10 analysts have issued 12 month price targets for Axsome Therapeutics' stock. Their forecasts range from $25.00 to $200.00. On average, they expect Axsome Therapeutics' share price to reach $99.80 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics. What is the consensus analysts' recommendation for Axsome Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics. Has Axsome Therapeutics been receiving favorable news coverage? Media coverage about AXSM stock has trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Axsome Therapeutics earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Axsome Therapeutics. Are investors shorting Axsome Therapeutics? Axsome Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 5,030,000 shares, a drop of 6.0% from the December 15th total of 5,350,000 shares. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is currently 3.7 days. Approximately 17.9% of the company's stock are short sold. View Axsome Therapeutics' Current Options Chain. Who are some of Axsome Therapeutics' key competitors? Some companies that are related to Axsome Therapeutics include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), The Medicines (MDCO) and Horizon Therapeutics (HZNP). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), Viking Therapeutics (VKTX), Netflix (NFLX), AT&T (T) and Arrowhead Pharmaceuticals (ARWR). Who are Axsome Therapeutics' key executives? Axsome Therapeutics' management team includes the folowing people: Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)Joseph Debrah-Afful, Director of Fin. When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.14%), Janney Montgomery Scott LLC (0.06%), Virginia Retirement Systems ET AL (0.04%), SG Americas Securities LLC (0.01%), McAdam LLC (0.01%) and UBP Investment Advisors SA (0.01%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics. Which major investors are selling Axsome Therapeutics stock? AXSM stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Axsome Therapeutics. Which major investors are buying Axsome Therapeutics stock? AXSM stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, SG Americas Securities LLC, McAdam LLC, UBP Investment Advisors SA, Huntington National Bank, Lindbrook Capital LLC and NEXT Financial Group Inc. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics. How do I buy shares of Axsome Therapeutics? Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $87.60. How big of a company is Axsome Therapeutics? Axsome Therapeutics has a market capitalization of $3.02 billion. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics. What is Axsome Therapeutics' official website? The official website for Axsome Therapeutics is http://axsome.com/. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241. MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 264 (Vote Underperform)Total Votes: 570MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?
